Arrowhead (NASDAQ: ARWR) CMO sells 10,000 shares in planned Form 4 trade

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals' Chief Medical Officer sells shares under a preset plan. Chief Medical Officer James C. Hamilton executed an open-market sale of 10,000 shares of Arrowhead Pharmaceuticals common stock at a weighted average price of $64.19 per share on March 5, 2026, under a Rule 10b5-1 trading plan. After this transaction, he directly owned 236,958 shares, which include previously reported restricted stock units that remain subject to vesting conditions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamilton James C

(Last) (First) (Middle)

177 EAST COLORADO BLVD

SUITE 700

(Street)

PASADENA CA 91105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		S(1)		10,000	D	$64.19(2)	236,958(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

2. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.80 to $64.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

3. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Remarks:

	/s/James Hamilton	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arrowhead Pharmaceuticals (ARWR) report for James C. Hamilton?

Arrowhead reported that Chief Medical Officer James C. Hamilton sold 10,000 shares of common stock. The sale was an open-market transaction executed under a Rule 10b5-1 trading plan at a weighted average price of $64.19 per share on March 5, 2026.

At what price did the Arrowhead Pharmaceuticals (ARWR) insider shares sell?

The reported weighted average sale price was $64.19 per share. The shares were sold in multiple transactions at prices ranging from $63.80 to $64.51, and detailed trade information is available upon request from Arrowhead Pharmaceuticals or the SEC staff.

How many Arrowhead Pharmaceuticals (ARWR) shares does James C. Hamilton hold after the sale?

After selling 10,000 shares, James C. Hamilton directly owned 236,958 Arrowhead Pharmaceuticals common shares. This total includes previously reported shares underlying restricted stock units, some of which are still subject to vesting conditions before becoming fully owned.

Was the Arrowhead Pharmaceuticals (ARWR) insider sale made under a Rule 10b5-1 plan?

Yes. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by James C. Hamilton. Such preset plans allow insiders to schedule trades in advance, following predefined instructions consistent with securities regulations.

What does the Form 4 footnote say about Arrowhead Pharmaceuticals (ARWR) sale price details?

The footnote explains the reported $64.19 figure is a weighted average sale price. Shares were sold in multiple trades between $63.80 and $64.51, and the reporting person will provide detailed trade data for each price level upon request.